Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation | Zendy

Thomas Van Stappen | Zendy; Lize Bollen | Zendy; Niels Vande Casteele | Zendy; Konstantinos Papamichael | Zendy; Gert Van Assche | Zendy; Marc Ferrante | Zendy; Séverine Vermeire | Zendy; Ann Gils | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation

Author(s) -

Thomas Van Stappen,

Lize Bollen,

Niels Vande Casteele,

Konstantinos Papamichael,

Gert Van Assche,

Marc Ferrante,

Séverine Vermeire,

Ann Gils

Publication year - 2016

Publication title -

clinical and translational gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.673

H-Index - 35

ISSN - 2155-384X

DOI - 10.1038/ctg.2016.62

Subject(s) - infliximab , medicine , ulcerative colitis , therapeutic drug monitoring , gastroenterology , trough level , tumor necrosis factor alpha , intraclass correlation , surgery , pharmacokinetics , clinical psychology , transplantation , disease , tacrolimus , psychometrics

Therapeutic drug monitoring of infliximab improves treatment outcomes, but available assays to monitor infliximab lack speed to implement treatment algorithms immediately. Our aim is to validate a rapid, lateral flow-based assay (LFA) for quantitative determination of infliximab and to assess thresholds associated with mucosal healing in patients with ulcerative colitis.status: publishe

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research